At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 334 enrolled
Drug / intervention
Ribavirin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects With Hepatitis C
In Brief
A Phase 2 clinical trial evaluating Ribavirin, Pegylated Interferon Alfa 2a, and 2 other interventions for Chronic Hepatitis C. Completed, enrolled 334 participants across 4 sites in 4 countries.
Detailed Summary
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
CountriesAustria, France, Germany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedSep 2006
Primary CompletionMay 2008
Study CompletionJun 2008
TodayJul 2026
First PostedSep 6, 2006
Enrollment StartAug 1, 2006
Primary CompletionMay 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.8 years ago
Interventions
Ribavirindrug
tablet
Pegylated Interferon Alfa 2adrug
Solution for injection
Placebodrug
tablet
Telaprevirdrug
tablet